Osteoporosis - Pipeline Review, H2 2016

Date: October 26, 2016
Pages: 296
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O01E16645AEEN
Leaflet:

Download PDF Leaflet

Osteoporosis - Pipeline Review, H2 2016
Osteoporosis - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H2 2016, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.

Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 7, 4, 8, 14, 1, 54 and 10 respectively for Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 8 and 13 molecules, respectively for Osteoporosis.

Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Osteoporosis Overview
Therapeutics Development
Osteoporosis - Therapeutics under Development by Companies
Osteoporosis - Therapeutics under Investigation by Universities/Institutes
Osteoporosis - Pipeline Products Glance
Osteoporosis - Products under Development by Companies
Osteoporosis - Products under Investigation by Universities/Institutes
Osteoporosis - Companies Involved in Therapeutics Development
Osteoporosis - Therapeutics Assessment
Drug Profiles
Osteoporosis - Dormant Projects
Osteoporosis - Discontinued Products
Osteoporosis - Product Development Milestones
Appendix 282

LIST OF TABLES

Number of Products under Development for Osteoporosis, H2 2016
Number of Products under Development for Osteoporosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Development by Companies, H2 2016 (Contd..1)
Number of Products under Development by Companies, H2 2016 (Contd..2)
Number of Products under Development by Companies, H2 2016 (Contd..3)
Number of Products under Development by Companies, H2 2016 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Products under Development by Companies, H2 2016 (Contd..1)
Products under Development by Companies, H2 2016 (Contd..2)
Products under Development by Companies, H2 2016 (Contd..3)
Products under Development by Companies, H2 2016 (Contd..4)
Products under Development by Companies, H2 2016 (Contd..5)
Products under Investigation by Universities/Institutes, H2 2016
Osteoporosis - Pipeline by Addex Therapeutics Ltd, H2 2016
Osteoporosis - Pipeline by Alethia Biotherapeutics Inc., H2 2016
Osteoporosis - Pipeline by Alize Pharma SAS, H2 2016
Osteoporosis - Pipeline by Alkem Laboratories Ltd., H2 2016
Osteoporosis - Pipeline by AlphaMab Co., Ltd, H2 2016
Osteoporosis - Pipeline by Alvogen Korea Co., Ltd., H2 2016
Osteoporosis - Pipeline by Amgen Inc., H2 2016
Osteoporosis - Pipeline by Amura Holdings Limited, H2 2016
Osteoporosis - Pipeline by Arcarios BV, H2 2016
Osteoporosis - Pipeline by BiologicsMD, Inc., H2 2016
Osteoporosis - Pipeline by Bone Biologics, Corp., H2 2016
Osteoporosis - Pipeline by Bone Therapeutics SA, H2 2016
Osteoporosis - Pipeline by Cellmid Limited, H2 2016
Osteoporosis - Pipeline by Chronos Therapeutics Limited, H2 2016
Osteoporosis - Pipeline by Chugai Pharmaceutical Co., Ltd., H2 2016
Osteoporosis - Pipeline by Corium International, Inc., H2 2016
Osteoporosis - Pipeline by Critical Pharmaceuticals Limited, H2 2016
Osteoporosis - Pipeline by Daiichi Sankyo Company, Limited, H2 2016
Osteoporosis - Pipeline by ElexoPharm GmbH, H2 2016
Osteoporosis - Pipeline by Eli Lilly and Company, H2 2016
Osteoporosis - Pipeline by EndoCeutics, Inc., H2 2016
Osteoporosis - Pipeline by Enteris BioPharma, Inc., H2 2016
Osteoporosis - Pipeline by Enzo Biochem, Inc., H2 2016
Osteoporosis - Pipeline by Gador S.A., H2 2016
Osteoporosis - Pipeline by Galapagos NV, H2 2016
Osteoporosis - Pipeline by Glide Pharmaceutical Technologies Limited, H2 2016
Osteoporosis - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016
Osteoporosis - Pipeline by Haoma Medica Ltd., H2 2016
Osteoporosis - Pipeline by Immunovo BV, H2 2016
Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd., H2 2016
Osteoporosis - Pipeline by Ipsen S.A., H2 2016
Osteoporosis - Pipeline by Kaken Pharmaceutical Co., Ltd., H2 2016
Osteoporosis - Pipeline by Lead Discovery Center GmbH, H2 2016
Osteoporosis - Pipeline by Ligand Pharmaceuticals, Inc., H2 2016
Osteoporosis - Pipeline by Merck & Co., Inc., H2 2016
Osteoporosis - Pipeline by Mereo Biopharma Group Plc, H2 2016
Osteoporosis - Pipeline by Midway Pharmaceuticals, Inc., H2 2016
Osteoporosis - Pipeline by Mithra Pharmaceuticals S.A., H2 2016
Osteoporosis - Pipeline by NIBEC, H2 2016
Osteoporosis - Pipeline by Novartis AG, H2 2016
Osteoporosis - Pipeline by Omeros Corporation, H2 2016
Osteoporosis - Pipeline by Oncobiologics, Inc., H2 2016
Osteoporosis - Pipeline by Oscotec Inc., H2 2016
Osteoporosis - Pipeline by OsteoGeneX Inc., H2 2016
Osteoporosis - Pipeline by Osteologix Holdings Plc., H2 2016
Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H2 2016
Osteoporosis - Pipeline by Pfenex Inc., H2 2016
Osteoporosis - Pipeline by PhytoHealth Corporation, H2 2016
Osteoporosis - Pipeline by R-Pharm, H2 2016
Osteoporosis - Pipeline by Recursion Pharmaceuticals, LLC, H2 2016
Osteoporosis - Pipeline by Ribomic Inc., H2 2016
Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., H2 2016
Osteoporosis - Pipeline by Shin Poong Pharm.Co., Ltd., H2 2016
Osteoporosis - Pipeline by Sinil Pharmaceutical Co., Ltd, H2 2016
Osteoporosis - Pipeline by STELIS Biopharma Pvt. Ltd., H2 2016
Osteoporosis - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016
Osteoporosis - Pipeline by TAmiRNA GmbH, H2 2016
Osteoporosis - Pipeline by TechnoPhage SA, H2 2016
Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H2 2016
Osteoporosis - Pipeline by TSH Biopharm Corporation Limited, H2 2016
Osteoporosis - Pipeline by Uni-Bio Science Group Ltd., H2 2016
Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H2 2016
Osteoporosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2016
Osteoporosis - Pipeline by Zydus Cadila Healthcare Limited, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Osteoporosis - Dormant Projects, H2 2016
Osteoporosis - Dormant Projects (Contd..1), H2 2016
Osteoporosis - Dormant Projects (Contd..2), H2 2016
Osteoporosis - Dormant Projects (Contd..3), H2 2016
Osteoporosis - Dormant Projects (Contd..4), H2 2016
Osteoporosis - Dormant Projects (Contd..5), H2 2016
Osteoporosis - Dormant Projects (Contd..6), H2 2016
Osteoporosis - Dormant Projects (Contd..7), H2 2016
Osteoporosis - Dormant Projects (Contd..8), H2 2016
Osteoporosis - Dormant Projects (Contd..9), H2 2016
Osteoporosis - Dormant Projects (Contd..10), H2 2016
Osteoporosis - Dormant Projects (Contd..11), H2 2016
Osteoporosis - Discontinued Products, H2 2016
Osteoporosis - Discontinued Products (Contd..1), H2 2016 279

LIST OF FIGURES

Number of Products under Development for Osteoporosis, H2 2016
Number of Products under Development for Osteoporosis - Comparative Analysis, H2 2016
Number of Products under Development by Companies, H2 2016
Number of Products under Investigation by Universities/Institutes, H2 2016
Comparative Analysis by Late Stage Development, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Products, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Top 10 Molecule Types, H2 2016
Number of Products by Stage and Top 10 Molecule Types, H2 2016
Skip to top


Post Menopausal Osteoporosis - Pipeline Review, H2 2016 US$ 2,000.00 Oct, 2016 · 85 pages
iCeutica, Inc. - Product Pipeline Review - 2015 US$ 1,200.00 Jul, 2015 · 31 pages

Ask Your Question

Osteoporosis - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: